LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Allogene Therapeutics Inc

Chiusa

SettoreSettore sanitario

1.43 11.72

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.3

Massimo

1.46

Metriche Chiave

By Trading Economics

Entrata

206K

-60M

EPS

-0.28

Margine di Profitto

272,450

Dipendenti

226

EBITDA

-302K

-56M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+500.78% upside

Dividendi

By Dow Jones

Utili prossimi

6 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

22M

278M

Apertura precedente

-10.29

Chiusura precedente

1.43

Notizie sul Sentiment di mercato

By Acuity

60%

40%

334 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Allogene Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 giu 2025, 14:31 UTC

Utili

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 giu 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 giu 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

6 giu 2025, 20:33 UTC

Utili

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 19:36 UTC

Discorsi di Mercato

Oil Futures Post Solid Weekly Gains -- Market Talk

6 giu 2025, 19:28 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 giu 2025, 18:46 UTC

Discorsi di Mercato

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 giu 2025, 18:02 UTC

Discorsi di Mercato

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 giu 2025, 16:35 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 16:34 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 16:21 UTC

Discorsi di Mercato

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

6 giu 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

6 giu 2025, 16:07 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

6 giu 2025, 16:07 UTC

Discorsi di Mercato

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 giu 2025, 15:53 UTC

Discorsi di Mercato

Mexican Inflation Seen Rising in May -- Market Talk

6 giu 2025, 15:36 UTC

Discorsi di Mercato

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 giu 2025, 15:36 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

6 giu 2025, 15:33 UTC

Discorsi di Mercato

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 giu 2025, 15:16 UTC

Discorsi di Mercato

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 giu 2025, 15:05 UTC

Discorsi di Mercato

Silver at its Highest In Nearly 15 Years -- Market Talk

6 giu 2025, 14:35 UTC

Discorsi di Mercato

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 giu 2025, 14:15 UTC

Discorsi di Mercato

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 giu 2025, 14:12 UTC

Utili

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 giu 2025, 14:09 UTC

Utili

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Confronto tra pari

Modifica del prezzo

Allogene Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

500.78% in crescita

Previsioni per 12 mesi

Media 7.75 USD  500.78%

Alto 14 USD

Basso 2.5 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Allogene Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

13 ratings

10

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.18 / 1.69Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

334 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.